Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial

Table 1 Dose escalation of FBTA05

FBT05	Day	Cohort A	Cohort B	Cohort C	Cohort D
Safety part	d0	10 μg	10 μg	10 μg	10 μg
	d3	20 μg	20 μg	20 μg	20 μg
	d7	50 μg	50 μg	100 μg	200 μg
FBT05	Day	Cohort A	Cohort B	Cohort C	Cohort D
Course I	d14	50 μg	50 μg	100 μg	200 μg
	d21	50 μg	50 μg	100 μg	200 μg
	d28	50 μg	50 μg	100 μg	200 μg
	d35	50 μg	100 μg	200 μg	300 μg
Course II	d42	50 μg	100 μg	200 μg	300 μg
	d49	50 μg	100 μg	200 μg	300 μg
	d56	50 μg	100 μg	200 μg	300 μg
	d63	50 μg	100 μg	200 μg	300 μg

ISSN: 1479-5876